At JPM26, MSD said it is derisking its Keytruda looming patent cliff. The company is waiting for 20 potential new product launches. At the same time, he expects 80 readings in the late stages of clinical trials. MSD says these milestones could double Keytruda's consensus forecast sales in 2028. Consensus sales are currently estimated at $35 billion. These expectations were announced at the JPM26 conference.